GoodRx Holdings Inc. (NASDAQ:GDRX), a leading healthcare technology company specializing in prescription drug discounts and telehealth services, finds itself at a critical juncture. As the company ...

Wrapping up Q3 earnings, we look at the numbers and key takeaways for the healthcare technology stocks, including GoodRx ...

For the third quarter, GoodRx booked revenue of just over $195.3 million, representing growth of 8% over the same period of 2023. Non-GAAP (adjusted) net income was $31.9 million, or $0.08 per share, ...

Key Insights Significant control over GoodRx Holdings by individual investors implies that the general public has ...

Analysts have recently evaluated GoodRx Holdings and provided 12-month price targets. The average target is $4.16, accompanied by a high estimate of $6.00 and a low estimate of $2.75. This current ...

GoodRx has seen a ~30% increase in its share price this year due to fundamental improvements and raised growth outlook. The company has seen a rebound in pharmacy transactions, leading to two straight ...

GoodRx, which specializes in prescription and telehealth services, saw its revenue rise by almost 3% year-over-year to just under $203 million. Non-GAAP (adjusted) net income also advanced, increasing ...

GoodRx offers compelling value after a ~50% stock decline over the past 12 months, trading at just 6.1x FY25 adjusted EBITDA despite recent execution challenges. A new Novo Nordisk partnership for ...

GoodRx (GDRX) is joining in on the GLP-1 action with an announcement on Monday that it will begin selling both of Novo Nordisk's (NVO) GLP-1 drugs, Ozempic for diabetes and Wegovy for weight loss, at ...